Selina M. Luger, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the current use of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) and what further investigations are needed to improve treatment strategies. Prof. Luger highlights how MRD is largely used to predict relapse in patients with ALL, with those achieving MRD negativity more likely to stay in remission. Those who are MRD positive must proceed to further therapy, usually blinatumomab, and allogeneic transplantation. Prof. Luger also comments on the unanswered questions around MRD in ALL, and the need for better technologies and treatment interventions for patients with T-cell ALL and Philadelphia chromosome positive (Ph+) disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.